1. Home
  2. KALV vs TRTX Comparison

KALV vs TRTX Comparison

Compare KALV & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

N/A

Current Price

$15.64

Market Cap

757.7M

Sector

Health Care

ML Signal

N/A

Logo TPG RE Finance Trust Inc.

TRTX

TPG RE Finance Trust Inc.

N/A

Current Price

$8.58

Market Cap

720.8M

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
KALV
TRTX
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
757.7M
720.8M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
KALV
TRTX
Price
$15.64
$8.58
Analyst Decision
Strong Buy
Buy
Analyst Count
5
3
Target Price
$30.00
$10.25
AVG Volume (30 Days)
564.9K
795.9K
Earning Date
04-13-2026
01-01-0001
Dividend Yield
N/A
11.35%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$108.37
$0.86
P/E Ratio
N/A
$14.82
Revenue Growth
495.66
N/A
52 Week Low
$9.83
$6.47
52 Week High
$19.00
$9.85

Technical Indicators

Market Signals
Indicator
KALV
TRTX
Relative Strength Index (RSI) 53.36 42.44
Support Level $14.45 $8.55
Resistance Level $16.33 $9.22
Average True Range (ATR) 0.69 0.21
MACD 0.07 -0.04
Stochastic Oscillator 80.05 37.35

Price Performance

Historical Comparison
KALV
TRTX

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About TRTX TPG RE Finance Trust Inc.

TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.

Share on Social Networks: